*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| No indexed studies for this compound. | ||
TB-4 Frag (Thymosin Beta-4 1-4) (Thymosin Beta-4 fragment (Ac-SDKP / AcSDKP, N-terminal tetrapeptide)). N-terminal tetrapeptide of Thymosin Beta-4 (Ac-Ser-Asp-Lys-Pro). Anti-fibrotic and anti-inflammatory; inhibits collagen deposition and modulates haematopoietic stem-cell proliferation.
Commonly discussed uses: anti-fibrotic research (cardiac/renal/pulmonary), tissue-repair research. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: N-terminal tetrapeptide of Thymosin Beta-4 (Ac-Ser-Asp-Lys-Pro). Anti-fibrotic and anti-inflammatory; inhibits collagen deposition and modulates haematopoietic stem-cell proliferation.
Reported considerations: limited human safety data. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical research peptide. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose, high research-defined. Administration: subcutaneous (research), infusion (animal models). Half-life: short (rapidly degraded by ACE).
Australian status: Not ARTG-registered; research. Preclinical research peptide. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: frozen aliquots.
Commonly discussed combinations (anecdotal for unapproved compounds): research peptide; no protocols. Stacking increases interaction/safety uncertainty.